383 related articles for article (PubMed ID: 25491234)
1. Pim kinases in hematological malignancies: where are we now and where are we going?
Mondello P; Cuzzocrea S; Mian M
J Hematol Oncol; 2014 Dec; 7():95. PubMed ID: 25491234
[TBL] [Abstract][Full Text] [Related]
2. Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies.
Koblish H; Li YL; Shin N; Hall L; Wang Q; Wang K; Covington M; Marando C; Bowman K; Boer J; Burke K; Wynn R; Margulis A; Reuther GW; Lambert QT; Dostalik Roman V; Zhang K; Feng H; Xue CB; Diamond S; Hollis G; Yeleswaram S; Yao W; Huber R; Vaddi K; Scherle P
PLoS One; 2018; 13(6):e0199108. PubMed ID: 29927999
[TBL] [Abstract][Full Text] [Related]
3. The PIM kinases in hematological cancers.
Alvarado Y; Giles FJ; Swords RT
Expert Rev Hematol; 2012 Feb; 5(1):81-96. PubMed ID: 22272708
[TBL] [Abstract][Full Text] [Related]
4. Identification of N-(4-((1R,3S,5S)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies.
Burger MT; Nishiguchi G; Han W; Lan J; Simmons R; Atallah G; Ding Y; Tamez V; Zhang Y; Mathur M; Muller K; Bellamacina C; Lindvall MK; Zang R; Huh K; Feucht P; Zavorotinskaya T; Dai Y; Basham S; Chan J; Ginn E; Aycinena A; Holash J; Castillo J; Langowski JL; Wang Y; Chen MY; Lambert A; Fritsch C; Kauffmann A; Pfister E; Vanasse KG; Garcia PD
J Med Chem; 2015 Nov; 58(21):8373-86. PubMed ID: 26505898
[TBL] [Abstract][Full Text] [Related]
5. Pan-PIM kinase inhibition provides a novel therapy for treating hematologic cancers.
Garcia PD; Langowski JL; Wang Y; Chen M; Castillo J; Fanton C; Ison M; Zavorotinskaya T; Dai Y; Lu J; Niu XH; Basham S; Chan J; Yu J; Doyle M; Feucht P; Warne R; Narberes J; Tsang T; Fritsch C; Kauffmann A; Pfister E; Drueckes P; Trappe J; Wilson C; Han W; Lan J; Nishiguchi G; Lindvall M; Bellamacina C; Aycinena JA; Zang R; Holash J; Burger MT
Clin Cancer Res; 2014 Apr; 20(7):1834-45. PubMed ID: 24474669
[TBL] [Abstract][Full Text] [Related]
6. Targeting the Pim kinases in multiple myeloma.
Keane NA; Reidy M; Natoni A; Raab MS; O'Dwyer M
Blood Cancer J; 2015 Jul; 5(7):e325. PubMed ID: 26186558
[TBL] [Abstract][Full Text] [Related]
7. PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers.
Brault L; Gasser C; Bracher F; Huber K; Knapp S; Schwaller J
Haematologica; 2010 Jun; 95(6):1004-15. PubMed ID: 20145274
[TBL] [Abstract][Full Text] [Related]
8. Pim Kinases Promote Migration and Metastatic Growth of Prostate Cancer Xenografts.
Santio NM; Eerola SK; Paatero I; Yli-Kauhaluoma J; Anizon F; Moreau P; Tuomela J; Härkönen P; Koskinen PJ
PLoS One; 2015; 10(6):e0130340. PubMed ID: 26075720
[TBL] [Abstract][Full Text] [Related]
9. Potential Pharmacological Inhibitors of Pim Kinase Under Clinical Trials.
Jeyapal GP; Chandrasekar MJN; Krishnasamy R; Selvaraj J; Mohammad M; Nanjan MJ
Anticancer Agents Med Chem; 2018; 18(8):1100-1114. PubMed ID: 29384063
[TBL] [Abstract][Full Text] [Related]
10. A serine/threonine protein PIM kinase as a biomarker of cancer and a target for anti-tumor therapy.
Panchal NK; Sabina EP
Life Sci; 2020 Aug; 255():117866. PubMed ID: 32479955
[TBL] [Abstract][Full Text] [Related]
11. Mechanism-based combinations with Pim kinase inhibitors in cancer treatments.
Yang Q; Chen LS; Gandhi V
Curr Pharm Des; 2014; 20(42):6670-81. PubMed ID: 25341939
[TBL] [Abstract][Full Text] [Related]
12. Targeting Pim kinases for cancer treatment: opportunities and challenges.
Le BT; Kumarasiri M; Adams JR; Yu M; Milne R; Sykes MJ; Wang S
Future Med Chem; 2015; 7(1):35-53. PubMed ID: 25582332
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and structure activity relationship of potent pan-PIM kinase inhibitors derived from the pyridyl carboxamide scaffold.
Nishiguchi GA; Burger MT; Han W; Lan J; Atallah G; Tamez V; Lindvall M; Bellamacina C; Garcia P; Feucht P; Zavorotinskaya T; Dai Y; Wong K
Bioorg Med Chem Lett; 2016 May; 26(9):2328-32. PubMed ID: 26995528
[TBL] [Abstract][Full Text] [Related]
14. Small molecule inhibitors of PIM1 kinase: July 2009 to February 2013 patent update.
Arunesh GM; Shanthi E; Krishna MH; Sooriya Kumar J; Viswanadhan VN
Expert Opin Ther Pat; 2014 Jan; 24(1):5-17. PubMed ID: 24131033
[TBL] [Abstract][Full Text] [Related]
15. The Pim kinases: new targets for drug development.
Swords R; Kelly K; Carew J; Nawrocki S; Mahalingam D; Sarantopoulos J; Bearss D; Giles F
Curr Drug Targets; 2011 Dec; 12(14):2059-66. PubMed ID: 21777193
[TBL] [Abstract][Full Text] [Related]
16. PIM protein kinases regulate the level of the long noncoding RNA H19 to control stem cell gene transcription and modulate tumor growth.
Singh N; Padi SKR; Bearss JJ; Pandey R; Okumura K; Beltran H; Song JH; Kraft AS; Olive V
Mol Oncol; 2020 May; 14(5):974-990. PubMed ID: 32146726
[TBL] [Abstract][Full Text] [Related]
17. Targeting Pim kinases in hematological cancers: molecular and clinical review.
Bellon M; Nicot C
Mol Cancer; 2023 Jan; 22(1):18. PubMed ID: 36694243
[TBL] [Abstract][Full Text] [Related]
18. Insulin receptor substrate 1 is a substrate of the Pim protein kinases.
Song JH; Padi SK; Luevano LA; Minden MD; DeAngelo DJ; Hardiman G; Ball LE; Warfel NA; Kraft AS
Oncotarget; 2016 Apr; 7(15):20152-65. PubMed ID: 26956053
[TBL] [Abstract][Full Text] [Related]
19. Discovery of ( R)-8-(6-Methyl-4-oxo-1,4,5,6-tetrahydropyrrolo[3,4- b]pyrrol-2-yl)-3-(1-methylcyclopropyl)-2-((1-methylcyclopropyl)amino)quinazolin-4(3 H)-one, a Potent and Selective Pim-1/2 Kinase Inhibitor for Hematological Malignancies.
Wang HL; Andrews KL; Booker SK; Canon J; Cee VJ; Chavez F; Chen Y; Eastwood H; Guerrero N; Herberich B; Hickman D; Lanman BA; Laszlo J; Lee MR; Lipford JR; Mattson B; Mohr C; Nguyen Y; Norman MH; Pettus LH; Powers D; Reed AB; Rex K; Sastri C; Tamayo N; Wang P; Winston JT; Wu B; Wu Q; Wu T; Wurz RP; Xu Y; Zhou Y; Tasker AS
J Med Chem; 2019 Feb; 62(3):1523-1540. PubMed ID: 30624936
[TBL] [Abstract][Full Text] [Related]
20. Use of regulators and inhibitors of Pim-1, a serine/threonine kinase, for tumour therapy (review).
Liang C; Li YY
Mol Med Rep; 2014 Jun; 9(6):2051-60. PubMed ID: 24737044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
